
Omlyclo set for line extension after EC approval
The European Commission (EC) has granted a line extension in the European Union for Omlyclo (omalizumab), Europe’s first and only omalizumab biosimilar. The EC approved Omlyclo 300mg/2ml prefilled syringe, following approval for 75mg/0.5ml and 150mg/1ml solutions in May 2024. Omlyclo is indicated for the treatment of patients with allergic asthma, chronic… Read More

